TERAPIA CELULAR Y MEDICINA REGENERATIVA

Foto de TERAPIA CELULAR Y MEDICINA REGENERATIVA

Foto de Maria Teresa

Maria Teresa
Cedena Romero

Publicaciones en las que colabora con Maria Teresa Cedena Romero (6)

2022

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
Therapeutic Advances in Hematology, Vol. 13

2021

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia, Vol. 35, Núm. 3, pp. 835-849

2017

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Leukemia Research, Vol. 63, pp. 85-89
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
Oncotarget, Vol. 8, Núm. 63, pp. 106948-106961

2016

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia
European Journal of Haematology, Vol. 97, Núm. 1, pp. 33-38

2015

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266